PATENT COOPERATION TREATY

PCT/IL2006/000015

From the INTERNATIONAL BUREAU





PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

G.E. EHRLICH (1995) LTD

11 Menachem Begin Street C E IVED

52521 Ramat Gar
ISRAEL

2 S AUG 2007

FILE No. 30780

G.E. EHRLICH (1995) LTD.

Date of mailing (day/month/year)
09 August 2007 (09.08.2007)

Applicant's or agent's file reference 30480

IMPORTANT NOTICE

International application No. PCT/IL2006/000015

International filing date (day/month/year)
04 January 2006 (04.01.2006)

Priority date (day/month/year)
04 January 2005 (04.01.2005)

Applicant

DUNE MEDICAL DEVICES LTD. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Simin Baharlou

Facsimile No. +41 22 338 82 70

:3

e-mail: pt09.pct@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 30480	FOR FURTHER ACTION	See item 4 below
International application No. PCT/IL2006/000015	International filing date (day/month/year) 04 January 2006 (04.01.2006)	Priority date (day/month/year) 04 January 2005 (04.01.2005)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant DUNE MEDICAL DEVICES LTD.		

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).		
2.	This REPORT consists of a total of 6 sheets, including this cover sheet. In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.		
3.	This report contains indications relating to the following items:		s:
	Box No. I Basis of the report		
	Box No. II	Priority	·
	Box No. III	Non-establishment of opin applicability	nion with regard to novelty, inventive step and industrial
	Box No. IV	Lack of unity of invention	
	Box No. V	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Certain defects in the international application	
	Box No. VI		
	Box No. VII		
	Box No. VIII Certain observations on the international		e international application
4.			gnated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but er Article 23(2), before the expiration of 30 months from the priority
			Date of issuance of this report 31 July 2007 (31.07.2007)
	The International Bur	eau of WIPO	Authorized officer
	34, chemin des Co	olombettes	Simin Baharlou

e-mail: pt09.pct@wipo.int

Facsimile No. +41 22 338 82 70 Form PCT/IB/373 (January 2004)

1211 Geneva 20, Switzerland

PATENT COOPERATION TREATY

TO. GAL EHRLICH G. E. EHRLICH (1995) LTD. II MENACHEM BEGIN STREET RAMAT GAN, ISRAEL \$2521 Applicant's or agent's file reference 30480 POR FURTHER ACTION See paragraph 2 below International application No. PCT/ILD6/00015 Ot January 2006 (04.01.2006) Ot January 2005 (04.01.2005) Ot January 2005 (04.01.2005) International Patent Classification (IPC) or both national classification and IPC DC: Acid Stock 2006.01) USPC: 600/407 Applicant DUNE MEDICAL DEVICES LTD. I. This opinion contains indications relating to the following items: Box No. II Basis of the opinion Box No. IV Lack of unity of invention Box No. IV Lack of unity of invention Box No. VI Lack of unity of invention Box No. VI Lock of unity of invention supplicability; citations and explanations supporting such statement Box No. VII Certain documents cited Box No. VII Certain defects in the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis/@) than written opinions of this internations are provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a ard the chosen IPEA has notified the International Bureau under Rule 66.1bis/@) than written opinions of this internations are provided above, considered to be a written opinion of the opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 32 months from the provided a	From the INTERNAT	'IONAL SEARC	HING AUTH	ORITY			
Applicant's or agent's file reference 30480 Applicant's or agent's file reference 30480 International application No. PCT/ILO6/00015 International application No. PCT/ILO6/00015 O4 January 2006 (04.01.2006) O4 January 2005 (04.01.2005) International Patent Classification (IPC) or both national classification and IPC IPC: A61B 5/05(2006.01) ISPC: A600407 Applicant DUNE MEDICAL DEVICES LTD. 1. This opinion contains indications relating to the following items: Box No. II Basis of the opinion Box No. II Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 436/s.1(a)(i) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain documents cited Box No. VII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority obter than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 60.16/s0 that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Date of completion of this opinion Authority date, whichever expires later. For further options, see Form PCT/ISA/220. Date of completion of this opinion Authority opinion Scape and Pales	GAL EHRLICH G. E. EHRLICH (1995) LTD. 11 MENACHEM BEGIN STREET		WRITTEN OPINION OF THE				
Adaymonth/sear 2 JUN 2Usf							
Adaymonth/sear 2 JUN 2Usf					Date of mailing	0.4	
International application No. International filing date (day/month/year) Priority date (day/month/year)	Applicant'	s or agent's file r	eference		(day/month/year)		
PCT/ILL06/00015 International Patent Classification (IPC) or both national classification and IPC IPC: A61B 5/05(2006.01) ISPC: 6004/07 Applicant DUNE MEDICAL DEVICES LTD. 1. This opinion contains indications relating to the following items: Box No. 1		o or agont a mor					
International Patent Classification (IPC) or both national classification and IPC IPC: A61B 5/08(2006.01) USPC: 600/407 Applicant DUNE MEDICAL DEVICES LTD. 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion	Internation	nal application No).	International filing date	(day/month/year) Priority date (day/month/year)		
IPC: A61B 5/05(2006.01) USPC: 600/407 Applicant DUNE MEDICAL DEVICES LTD. 1. This opinion contains indications relating to the following items: Box No. 1						04 January 2005 (04.01.2005)	
SPC: 600/407	1			or both national classificat	ion and IPC		
1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion	1						
1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion	1 ''						
Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents eited Box No. VII Certain defects in the international application Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen DPEA has notified the international Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandrix, Virginia 22313-1450 Alexandrix, Virginia 22313-1450 Facsimile No. (371) 273-3201	DUNE ME	DICAL DEVICE	ES LTD.				
Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Burcau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Bos 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Facsimile No. (371) 273-3201	1. This opinion contains indications relating to the following items:						
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the BPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephore No. VI-800-786-9757		Box No. I Basis of the opinion					
Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis. 1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephore No. U-800-786-9757		Box No. II	Priority				
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(2) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Patentifications and explanations supporting such statement International preliminary examination is made, this opinion will be considered to be a written opinion will be considered to be a written opinion of the International Planation of the International Planatio		Box No. III	Non-establis	shment of opinion with reg	gard to novelty, inve	entive step and industrial applicability	
applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Certain defects in the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220. Date of completion of this opinion Authorized of ficery Alexandria, Virginia 22313-1450 Telephone No. Vi-800-786-9757 Telephone No. Vi-800-786-9757		Box No. IV					
Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atta: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. II-800-786-9757	\boxtimes	Box No. V					
Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Date of completion of this opinion Authorized officer Telephone No. Vi-800-786-9757		Box No. VI		•	5		
Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the international Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Date of completion of this opinion Authorized officer Telephone No. Vi-800-786-9757		Box No. VII	Certain defe	cts in the international app	lication	cation	
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Telephone No. Vi-800-786-9757		Box No. VIII					
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Telephone No. Vi-800-786-9757	2. FURT	CHER ACTIO	N				
IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Date of completion of this opinion 24 May 2007 (24.05.2007) Telephone No. 1-800-786-9757	if a de Interna Author	emand for international Prelimination	ational preliming Examining is one to be the	g Authority ("IPEA") exc he IPEA and the chosen I	cept that this does PEA has notified the	not apply where the applicant chooses an the International Bureau under Rule 66.1bis(b)	
3. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Date of completion of this opinion 24 May 2007 (24.05.2007) Eleti M Mantis-Mercader Telephone No. 1-800-786-9757	IPEA :	written reply to	gether, where	appropriate, with amendr	nents, before the ex	piration of 3 months from the date of mailing	
Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/ US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Date of completion of this opinion 24 May 2007 (24.05.2007) Elevi M Mantis-Marcader Telephone No. 1-800-786-9757	For fur	ther options, see	Form PCT/IS.	A/220.			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 24 May 2007 (24.05.2007) Telephone No. 1-800-786-9757	3. For further details, see notes to Form PCT/ISA/220.						
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 24 May 2007 (24.05.2007) Telephone No. 1-800-786-9757		•		Date of complet	ion of this opinion	Authorized officery	
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Telephone No. 1-800-786-9757				24 May 2007 (2-	4.05.2007)	Eleki M Mantis-Mercader	
Facsimile No. (571) 273-3201	P.O. Box 1450						
Form PCT/ISA/237 (cover sheet) (April 2005)	Facsimile N	lo. (571) 273-320	1			Telephone No. VI-800-786-9757	

International application No.

PCT/IL06/00015

BOX NO. 1 Basis of this opinion
·
1. With regard to the language, this opinion has been established on the basis of:
the international application in the language in which it was filed
a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material
a sequence listing
table(s) related to the sequence listing
b. format of material
on paper
in electronic form
c. time of filing/furnishing
contained in the international application as filed.
filed together with the international application in electronic form.
· ·
furnished subsequently to this Authority for the purposes of search.
In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:
F DOTTE A D27/Dow No. D (A

Form PCT/ISA/237(Box No. I) (April 2005)

International application No. PCT/IL06/00015

Statement			
Novelty (N)	Claims	5-9,11-12,32-35,44-58,63-68	YES
		1-4,10,13-31.36-43.59-62.69	NO
Inventive step (IS)	Claims	NONE	YES
,	Claims		NO
Industrial applicability (IA)	Claims	1-69	YES
	Claims		NO
Citations and explanations:		,	·
ase See Continuation Sheet			
<u>C.</u>			
•			

International application No. PCT/IL06/00015

	Supplemental Box
	In case the space in any of the preceding boxes is not sufficient.
_	

V. 2. Citations and Explanations:

Claims 1-4, 10, 13-31, 36-43 and 69 lack novelty under PCT Article 33(2) as being anticipated by Bambot et al. Bambot et al. disclose an endoscope that uses optical fibers to serve as a nonirradiative electromagnetic sensor (column 10, lines 27 through column 11, line 14). They disclose that their invention can be used in various situations, such as in vivo detection of diseased tissues (i.e cancerous tissues) (column 3, lines 60-67). Their invention includes a processor (44), as well as a frequency synthesizer (46) and a detector (56). See Figure 1. The endoscope is introduced into a natural lumen or a cavity of a patient's body, such as an oral cavity, a nostril, etc. (column 4, lines 1-18). Their endoscope includes an optical fiber bundle (54) that serves as a communication line (column 10, lines 27-36). The endoscope further includes a long body portion that may be inserted into a body of the patient (i.e. intracorporeal portion) as well as a hande (i.e. extracorporeal portion) that can be used for positioning the endoscope (column 10, lines 37-54). They further disclose that a device (i.e. second instrument) may be positioned on a distal end of the endoscope (column 10, lines 37-44). The device may be used to remove tissue samples from a patient (i.e. biopsy), introduce a dose of medication to a target tissue, or be used to deliver therapeutic radiation (column 10, lines 37-44). Bambot et al. further disclose a method using their invention for tissue characterization (column 11, lines 46-60).

Claims 5-7, 44-45, and 47-50 lack an inventive step under PCT Article 33(3) as being obvious over Bambot et al. in view of Bladen et al. Bambot et al. do not disclose that the nonirradiative electromagnetic sensor may be removed and replaced with another instrument. Further, they do not disclose that their endoscope further includes a catheter that can extend beyond a distal-most end of the endoscope and can be manipulated independently of the endoscope. Bladen et al. disclose an endoscope wherein a sensor can be placed inside the biopsy channel of an endoscope (pg.6-7, paragraphs [0102]-[0103]). They further disclose that the endoscope passes the sensor down the tip of the biopsy channel until it reaches the tip of the endoscope (pg. 7, paragraph [0106]). The sensor is encapsulated within a hollow tubular catheter which is routinely used with endoscopes (pg. 7, paragraph [0106]). The catheter can then be withdrawn (pg. 7, paragraph [0106]). At the time of the invention, it would have been obvious to one of ordinary skill in the art to include with the endoscope of Bambot et al. a removable sensor, as well as a catheter. The motivation for doing so would have been to provide information about the path of the endoscope and catheters are routinely used with endoscopes, as taught by Bambot et al. (pg. 6, paragraph [0101] and pg. 7, paragraph [0106]).

Claims 8-9 and 32 lack an inventive step under PCT Article 33(3) as being obvious over Bambot et al. in view of Nakaichi et al. Bambot et al. do not disclose that the intracorporeal portion further includes an optical channel for an optical instrument, nor that that the optical instrument is configured to observe the nonirradiative electromagnetic sensor. Nakaichi et al. disclose an endoscope for optically

Form PCT/ISA/237 (Supplemental Box) (April 2005)

International application No. PCT/IL06/00015

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

observing the body cavity of the patient (column 1, lines 7-17). They further disclose that an image transmitting optical fiber bundle and an illumination light transmitting optical fiber bundle are incorporated within the insertion unit of the endoscope (i.e. intracorporated portion) (column 6, lines 44-56). At the time of the invention, it would have been obvious to one of ordinary skill in the art to have included an optical channel for an optical instrument, and have the optical instrument configured to observe the nonirradiative electromagnetic sensor. The motivation for doing so would have been to be able illuminate the cavity and enable an image of the body cavity to be observed as taught by Nakaichi et al. (column 1, line 65 through column 2, line 6).

Claims 11-12 and 33-35 lack an inventive step under PCT Article 33(3) as being obvious over Bambot et al. in view of Nevo et al. Bambot et al. do not disclose that the second instrument is selected from the group consisting of an optical sensor, an x-ray sensor, an ultrasound sensor, an MR sensor, etc., nor that the second instrument is configured to sense the nonirradiative electromagnetic sensor. Nevo et al. discloses that their invention includes the use of a separate set of tracking coils for tracking purposes (i.e. electromagnetic sensor), and a separate set of imaging coils for imaging purposes (i.e. MR sensor) (pg. 6, paragraph [0076], pg.3, paragraph [0029]). At the time of the invention, it would have been obvious to one of ordinary skill in the art to include in the invention of Bambot et al. a second instrument selected from group listed above. The motivation for doing so would have been to enable the instrument to image selected areas within the body cavity, as taught by Nevo et al. (pg.3, paragraph [0028]).

Claim 46 lacks an inventive step under PCT Article 33(3) as being obvious over the prior art as applied in the immediately preceding paragraph and further in view of Nevo et al. Bambot et al. in view of Bladen et al. do not disclose that the sensor for tissue characterization is selected from the group consisting of an optical sensor, an x-ray sensor, an MR sensor etc. Nevo et al. disclose that their invention includes the use of a separate set of tracking coils for tracking purposes (i.e. electromagnetic sensor), and a separate set of imaging coils for imaging purposes (i.e. MR sensor) (pg. 6, paragraph [0076], pg.3, paragraph [0029]). At the time of the invention, it would have been obvious to one of ordinary skill in the art to include in the invention of Bambot et al. a sensor selected from the group listed above. The motivation for doing so would have been to enable the instrument to image selected areas within the body cavity, as taught by Nevo et al. (pg.3, paragraph [0028]).

Claims 59-62 lack novelty under PCT Article 33(2) as being anticipated by Nevo et al. Nevo et al. disclose an endoscopic examining apparatus that has an integrated imaging and tracking capability (pg. 3, paragraph [0026]). The tracking system uses miniature sensors that senses electromagnetic fields generated by an MR scanner (pg. 3, paragraphs [0024] and [0025]). The probe has a hollow construction in which a guidewire may be inserted for injection of contrast material, biopsy, or for other diagnostic or interventional procedures that may be required (pg. 4, paragraph [0038]). They further disclose that their invention includes the use of a separate set of tracking coils for tracking purposes (i.e. electromagnetic sensor), and a separate set of imaging coils for imaging purposes (i.e. MR sensor) (pg. 6, paragraph [0076], pg.3, paragraph [0029]).

Claims 51-58 and 63-68 lack an inventive step under PCT Article 33(3) as being obvious over Nevo et al. in view of Bambot et al. Nevo et al. do not disclose that a second instrument is inserted, mounted on a second communication line, intracorporeally, along the guide wire. They also do not disclose that the instrument can be a biopsy instrument, configured for localized surgery, or for dispensing medication. Bambot et al. disclose that a separate device (i.e.instrument) may be included with the endoscope and used to remove tissue samples from a patient, introduce a dose of medication, or emit therapeutic radiation (column 10, lines 37-44). At the time of the invention, it would have been obvious to one of ordinary skill in the art to include with the endoscope a second instrument. The motivation for doing so would have been to be able to perform multiple functions, as taught by Bambot et al. (column 10, lines 37-44).

Claims 1-69 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.